Biotech Values

[DewDiligence]

If this is verified, do you think it is something mnta should mention on their conference call?

That’s a good question, and I’m not sure what the answer is insofar as MNTA has two conflicting goals: i) doing what is best for shareholders; and ii) not being seen as vindictive in discussing a matter that is not under MNTA’s control.

If MNTA’s concern for shareholders extends only to bona fide investors rather than traders and options players, declining to comment in detail on Teva’s ANDA is probably the right thing to do. The facts will come out in due course, regardless of what MNTA does or does not say on the upcoming CC.